Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration.
about
A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen designMathematical model of plasmid-mediated resistance to ceftiofur in commensal enteric Escherichia coli of cattleDistinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic ModelingSemimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa.Population dynamics of antibiotic treatment: a mathematical model and hypotheses for time-kill and continuous-culture experiments.PA-824 exhibits time-dependent activity in a murine model of tuberculosis.Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.Novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies.Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus.Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans.A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro.Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing designReassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignanciesFunctional relationship between bacterial cell density and the efficacy of antibiotics.A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.In vitro pharmacodynamic models to determine the effect of antibacterial drugs.Pharmacological considerations for the proper clinical use of aminoglycosides.Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary.Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.Translational PK/PD of anti-infective therapeutics.Time-kill kinetics of antibiotics active against rapidly growing mycobacteria.Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?Relationship between pharmacodynamic indices and killing patterns in vitro.Evaluation of pharmacokinetic/pharmacodynamic relationships of PD-0162819, a biotin carboxylase inhibitor representing a new class of antibacterial compounds, using in vitro infection models.Prediction of in vivo and in vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms.Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.Pharmacodynamics and differential activity of nitrofurantoin against ESBL-positive pathogens involved in urinary tract infections.The PK/PD Interactions of Doxycycline against Mycoplasma gallisepticum.Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli.Comparison of different in vitro tests to detect Cryptococcus neoformans not susceptible to amphotericin B.Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.Pharmacodynamics of nitrofurantoin at different pH levels against pathogens involved in urinary tract infections.Monte Carlo Simulations Suggest Current Chlortetracycline Drug-Residue Based Withdrawal Periods Would Not Control Antimicrobial Resistance Dissemination from Feedlot to Slaughterhouse.Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection.
P2860
Q28476705-64985791-A586-4BE3-AADF-597B90D0DA99Q28483752-45853D08-4F66-4099-A314-5D7FCA25E6F4Q28550711-02E7AB28-17EE-461B-855B-BB3D6665FF84Q33876563-8F767907-A0E2-4DB6-AAAF-C22D9003C140Q34045319-62794AAC-AA3D-49F1-8E5C-4F0B7E89E53DQ34483632-73BCB5D4-9641-49E4-ADE6-5F2A05C4F08EQ34680516-9ECAAFC4-70FB-4391-B90C-A935AABB1054Q34922570-80731EEE-EE4C-4A29-B83B-9F4CB01FAD47Q35023303-5400687B-CF3F-4258-8FDF-F27C970F8592Q35127800-24D1A426-041B-4DD4-AA52-C229257BE4A0Q35168882-BB55DCD4-8AE6-4DD3-8952-9B8C72815318Q36072639-90BE2B7A-2866-4B3A-9F76-1C8BB914D77BQ36439179-058FDE18-AB2B-45DA-B335-8C10B68DCE0AQ36482785-A86CA4A0-DAAD-49F7-9786-E4A45D003235Q36684146-F122DDD8-5E3E-4A16-8E38-88579A6FB9B0Q36785827-EF23F185-BFD9-417D-808F-12512B3EFE42Q37072039-24826F70-9AEB-4890-9C1E-64BE171F22D0Q37124158-05F941ED-68E2-40F7-9A4A-1B239D246B52Q37441394-A594F843-BE7D-471B-B617-0EE0FA5F9967Q37660762-6D067F76-7023-4D07-8206-D7A9B815CCE6Q37956403-68BB977B-C50B-4D67-9A69-C924C8607471Q38077518-1D0490EB-DB20-482F-BC75-DCBD5B45AF94Q38117578-15A3F586-6D26-4FB0-B535-6E1A5A30EB69Q38664871-14548537-9B08-402D-91B3-910C761BA732Q38914243-2B8CFCB4-C733-437D-A554-D358D99DEE42Q39039505-EABCCEFB-89B0-48E9-9009-E53557730D17Q39108163-242EC8AE-0115-47B8-B20F-BB72FCED0B5CQ39344408-FC7499DA-8180-47FD-9591-F4DCBABCF680Q39735382-E46BD8A4-C1B9-43B3-8FDF-7D62310082E2Q40327149-6465B87F-A851-4352-AC13-187D57D7BF65Q40350783-6BBA2F9E-9C81-49E0-9B4A-D12242DEFC97Q40375783-B5E6642F-3F22-4642-88C4-B88E4BC64BAFQ40640027-AE3691F3-FD9B-4F6E-9128-CC0719D5C06CQ40666520-0CA6D188-FC57-4E59-B4F4-230CF0C44FC6Q40666822-F6E1DE69-8515-416D-A4C0-C48074BFDDDAQ41472967-5EC87BD7-1817-4A9F-A057-71631DF4DC65Q41879559-45426DDA-6A60-4F80-8CEF-FC3C86D1D952Q41992952-387D2AFC-ACAE-4AAC-AC6C-A2367E1A34D1Q42369943-6B176CA2-2D33-41E1-948C-32343A7AB00AQ43152276-BC2F4543-E8E0-4C8F-AD93-3C99A0E809A2
P2860
Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Pharmacokinetic/pharmacodynami ...... rsus stationary concentration.
@en
Pharmacokinetic/pharmacodynami ...... rsus stationary concentration.
@nl
type
label
Pharmacokinetic/pharmacodynami ...... rsus stationary concentration.
@en
Pharmacokinetic/pharmacodynami ...... rsus stationary concentration.
@nl
prefLabel
Pharmacokinetic/pharmacodynami ...... rsus stationary concentration.
@en
Pharmacokinetic/pharmacodynami ...... rsus stationary concentration.
@nl
P1476
Pharmacokinetic/pharmacodynami ...... ersus stationary concentration
@en
P2093
Alexander A Vinks
P304
P356
10.2165/00003088-200544020-00005
P577
2005-01-01T00:00:00Z
P6179
1003460249